HHS peptide compounding policy lets small pharmacies make six unapproved peptides

The Department of Health and Human Services said on October 28 that it will not go after small compounding pharmacies that make six unapproved peptides, including BPC-157. The peptide compounding policy, issued as an enforcement discretion notice, aims to pull buyers away from research use only products sold online. It does not approve any of the six, it leaves out the larger outsourcing plants, and pharmacists warn that supply will be thin at first. Here is who is covered, what conditions apply and what is still unclear.

What HHS changed for six peptides

In a notice filed on Wednesday, October 28, HHS said it would use enforcement discretion for six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500, according to NBC News. In plain terms, the department told the FDA not to take legal action against licensed pharmacies that compound them. None of the six is approved by the FDA, and none is on the bulk drug substances list, the official roster of ingredients that compounders may normally use. Adding a substance to that list takes a proposed rule, public comment and a final rule, which can run for months. NBC reported that the peptide compounding policy is a stopgap while that rule work goes on, so the six stay unapproved drugs even as the threat of enforcement is lifted.

The relief is narrow. NPR reported that it covers only 503A pharmacies, the smaller shops that fill prescriptions for individual patients, and not the 503B outsourcing facilities that produce higher volumes. The notice also comes with conditions. Pharmacies must vouch that each peptide is genuine and pure, and they must report side effects, a duty that was not required before, NBC reported. The Associated Press said FDA staff helped draft guardrails such as using ingredients from FDA registered factories. According to the document, Kennedy found that the change "advances patient choice and freedom" and shields people from online peptides of uncertain origin. An interim version had gone to the White House for review earlier this month, as covered in our earlier report on the policy.

Why enforcement discretion is not approval

Enforcement discretion is a promise not to act, not a finding that a product is safe or works. That gap sits at the center of the fight. In July, an FDA advisory panel narrowly voted to add the six peptides to the bulk list, but at the same meeting the agency's own scientists recommended keeping the limits in place. Six of the panel members were new appointees linked to the peptide business, NBC reported. The Associated Press, citing six people familiar with the work, said FDA drug staff had little say and pushed back on the policy. Those people said HHS first wanted a formal rule declaring the peptides fit for compounding, and switched to the current approach after FDA officials warned that agency scientists would not support it.

Enforcement discretion is a promise not to act, not a finding that a product is safe or works.

Critics also doubt that the safeguards can be enforced. Peter Lurie, who once worked at the FDA and now heads the watchdog group Center for Science in the Public Interest, told the AP that federal law gives the agency no power to enforce the pharmacy requirements in the notice. Public Citizen said Kennedy appeared to act on his own rather than through normal rulemaking. "Kennedy has undermined the FDA and threatened public health," said Dr. Robert Steinbrook, director of the group's Health Research Group, according to NPR. The AP described the document as a draft and said public comments will be accepted for two weeks before the text is made final. The terms could still change, and a policy built on discretion rather than a final rule offers pharmacies less legal certainty.

Who can make the peptides and how soon

Supply looks like the first bottleneck for 503A pharmacies. The president of a compounding company in central Florida told NPR that people have asked about these peptides for years, but his firm did not make them while they were illegal to compound. Under the new terms only his smaller facility qualifies, in small amounts, and it will likely make just one of the six after it prepares the site. "We won't be able to meet demand," he said. "I don't think all the [503]As in the country could meet the demand." Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, welcomed the peptide compounding policy as a "more accountable alternative" to gray market products, but warned that dispensing may take time.

The delay starts in the ingredient chain. Brunner said ingredient makers first have to prove that their raw material satisfies the new terms, and each pharmacy then has to check that proof. His group also told the AP that key details remain open, including the start date and how the federal terms fit with state pharmacy boards, which have long been the main regulators of pharmacists. Reports differ on timing: NBC said pharmacies can start offering the peptides now, while the AP said comments will run for two weeks before the measure is final. State boards already act on peptide sales by themselves, as an Ohio license suspension showed this month. Both the Florida owner and Brunner point to limited and uneven availability at first.

What it means for research use only peptides

HHS presents the move as a safety step. The notice calls compounding a safer route than illicit research use only peptides sold online, which NPR said are often sourced from questionable suppliers overseas. Those products carry labels claiming they are not meant for humans, a legal workaround NBC described. HHS spokesperson Emily Hilliard said the department is confronting "the risks of black-market peptides." There is money behind the shift too. The AP reported that major telehealth providers have said they intend to add wellness peptides after the federal rules shift, and analysts on Wall Street put the possible market above $2 billion. Lurie questioned the timing, days before the midterm election, and called the move "a wink and nod to the MAHA faithful".

Opponents say the change blurs a line patients rely on. The Partnership for Safe Medicines, which includes pharmacy and pharmacist groups, filed its citizen petition asking the FDA to set aside its advisers' July vote. Executive director Shabbir Safdar told NBC that the policy would expose Americans to "untested dangerous substances." Harm linked to unapproved peptides is already being counted abroad, with emergency visits in New South Wales rising this year. Steinbrook urged clinicians to warn patients that contamination and other side effects are possible. For readers, the plain point is this: a peptide compounded by a licensed pharmacy still has had no FDA review of safety or benefit, and online research products carry contamination and counterfeit risk without that oversight.

Conclusion

The HHS peptide compounding policy lifts the threat of federal action against small 503A pharmacies that make six unapproved peptides, on conditions covering sourcing, purity and side effect reporting. It approves nothing, leaves out larger outsourcing plants and has no confirmed start date. FDA scientists opposed it, critics doubt its guardrails can be enforced, and pharmacists expect supply to trail demand. Watch for the final text after the comment period, guidance from state boards and the first safety reports. This story is for information only and is not medical advice.